FDA expands age indication for STAAR’s EVO ICL to patients aged 21–60 years
The FDA has approved an expanded age indication for STAAR Surgical Company's EVO/EVO+ Visian Implantable Collamer Lenses, now allowing use for patients aged 21 to 60 years, up from the previous 21 to 45 years. This expansion is based on three-year FDA clinical trial safety data showing a strong safety profile and is expected to significantly increase STAAR's addressable US market. The company highlights a shift in refractive procedure trends, with EVO ICL implantations increasing while laser-based procedures decline, indicating growing patient and surgeon interest in lens-based approaches for myopia correction.
FDA approves expanded age indication for STAAR's EVO/EVO+ Visian ICLs
The FDA has approved an expanded age indication for STAAR Surgical Company's EVO/EVO+ Visian Implantable Collamer Lenses (ICLs), extending the age range from 21-45 to 21-60. These ICLs are designed for myopia and astigmatism correction through a reversible, minimally-invasive procedure. The approval is supported by 3-year safety data from an FDA clinical study and real-world insights from a retrospective study, highlighting the ICL's strong safety profile and potential for broader use in refractive surgery.
FDA Approves Expanded Age Range for STAAR Surgical’s EVO ICL for Vision Correction
The FDA has approved an expanded age range for STAAR Surgical's EVO/EVO+ Visian ICL, allowing its use for vision correction in patients aged 21 to 60, up from 21-45. This decision, backed by positive three-year clinical trial safety data, is expected to significantly increase the addressable market for the EVO ICL in the U.S. Amid a decline in laser-based refractive procedures, STAAR Surgical notes a growing interest in and adoption of lens-based solutions, particularly for higher myopia.
Midday Stock Roundup: Staar Surgical up on FDA approval
Staar Surgical saw its stock rise by 5% following FDA approval to expand the age indication for its EVO/EVO+ Visian Implantable Collamer Lenses, significantly increasing its addressable market in the U.S. Conversely, Beta Bionics experienced a 7% drop in share price after reporting a wider net loss for 2025, leading an analyst firm to cut its target price. Glaukos, another medtech company, reported record fourth-quarter net sales, causing its stock to climb 8.9%.
FDA expands age indication for Staar Surgical EVO ICL
Staar Surgical announced that the FDA has expanded the age indication for its Evo Visian Implantable Collamer Lenses (ICL) to include patients between 21 and 60 years old, up from the previous 21 to 45. This expansion follows three-year clinical data confirming the long-term safety of EVO ICL, significantly increasing the addressable market in the U.S. The company notes a growing trend towards lens-based vision correction alternatives as laser-based procedures decline.
Why Is Staar Surgical Stock Gaining Wednesday? - Staar Surgical (NASDAQ:STAA)
Staar Surgical Company's stock is rising after the FDA expanded the age indication for its EVO/EVO+ Visian Implantable Collamer Lenses (ICL) to include patients aged 21 to 60. This expansion could add nearly 8 million new patients to the market, driven by increasing patient preference for lens-based vision correction alternatives. Despite a bearish short-to-medium-term technical outlook and being oversold, the FDA approval highlights a significant growth opportunity for the company ahead of its earnings report.
Staar Surgical Gains Key FDA Approval to Broaden Patient Eligibility
Staar Surgical has received a significant FDA approval, expanding the eligible age range for its EVO and EVO+ implantable collamer lenses (ICLs) up to 60 years old. This move substantially increases the potential patient population for the company's vision correction technology, especially as traditional laser-based procedures decline. The company is also undergoing a leadership transition following a failed merger attempt with Alcon, with new interim Co-CEOs now tasked with capitalizing on this regulatory advantage.
FDA Expands U.S. Age Indication for EVO ICL as Long-Term Safety Data Reinforces Market Shift Away From Laser Vision Correction
STAAR Surgical (NASDAQ: STAA) announced that the FDA has expanded the age indication for its EVO/EVO+ Visian Implantable Collamer Lenses (EVO ICL) to include patients aged 21 to 60, up from the previous 21 to 45. This expansion, supported by three-year FDA clinical trial safety data, makes the EVO ICL available to an additional 8 million refractive patients in the U.S. The approval comes amidst a growing shift in the U.S. vision correction market away from laser-based procedures, with EVO ICL becoming the leading procedure for patients with high myopia.
Credit Industriel ET Commercial Invests $3.26 Million in STAAR Surgical Company $STAA
Credit Industriel ET Commercial has invested $3.26 million in STAAR Surgical Company by acquiring 121,258 shares, representing approximately 0.25% ownership. Analyst sentiment for STAAR Surgical is mixed to negative, with a consensus "Reduce" rating and a target price of $20.91, while institutional investors hold a significant portion of the stock. Insider buying has been notable, particularly a large purchase by Broadwood Partners, though the stock is trading near its 52-week low.
STAAR Surgical Company (STAA) Stock Analysis: Exploring a 37.81% Potential Upside for Investors
STAAR Surgical Company (STAA), a medical instruments and supplies firm, shows a potential upside of 37.81% despite recent market fluctuations and current operating losses. The company, which specializes in implantable eye lenses, has a market capitalization of $814.04 million and its stock is trading at $16.49, with analysts giving mixed ratings but an average target price suggesting significant growth. Investors should balance the promising growth potential, positive free cash flow, and revenue growth with concerns about negative net income, ROE, and a high forward P/E ratio.
New York Life Investment Management LLC Takes Position in STAAR Surgical Company $STAA
New York Life Investment Management LLC has acquired a new stake of 83,482 shares, valued at approximately $2.24 million, in STAAR Surgical Company (NASDAQ:STAA) during the third quarter. Despite this, analyst sentiment leans towards a "Reduce" rating with an average price target of $20.91, while the stock currently trades lower and below its moving averages. Notably, insiders and institutional investors have also been active, with significant buying from Broadwood Partners and a high institutional ownership percentage.
Alpine Associates Management Inc. Acquires Shares of 913,087 STAAR Surgical Company $STAA
Alpine Associates Management Inc. has acquired a new position of 913,087 shares in STAAR Surgical Company (NASDAQ:STAA), valued at approximately $24.5 million, making it their 16th largest holding. Other institutional investors like Amalgamated Bank and CWM LLC also increased their stakes. The article also covers STAAR Surgical's price performance, recent analyst ratings, and insider buying activity, noting a significant purchase by Broadwood Partners, L.P.
ABC Arbitrage SA Buys Shares of 246,829 STAAR Surgical Company $STAA
ABC Arbitrage SA recently acquired 246,829 shares of STAAR Surgical Company ($STAA) during the third quarter, valued at approximately $6.63 million, establishing a new position in the company. Other institutional investors also adjusted their holdings in STAAR Surgical, which currently has a "Reduce" consensus rating from analysts with an average price target of $20.36. Insider trading data shows significant buying activity from a major shareholder and other insiders in the last 90 days.
STAAR Surgical Company (NASDAQ:STAA) Given Average Recommendation of "Reduce" by Analysts
STAAR Surgical Company (NASDAQ:STAA) has received an average "Reduce" rating from analysts, with a consensus 12-month price target of $20.36. Insider activity shows Broadwood Partners recently purchased over 27,000 shares, and insiders collectively bought approximately 1.93 million shares worth over $50 million in the past 90 days. Institutional investors and hedge funds hold a significant 96.70% of the company's stock.
STAAR Surgical stock price target lowered to $19 by Stifel on China concerns
Stifel has lowered its price target for STAAR Surgical (NASDAQ:STAA) to $19.00 from $28.00, maintaining a Hold rating due to concerns about the Chinese refractive market. The firm identified persistent uncertainty and soft procedure volumes in China, despite the company's Implantable Collamer Lens (ICL) gaining market share. Stifel awaits signs of improvement in the Chinese market and stability in management before adopting a more positive outlook on the stock.
STAAR Surgical stock price target lowered to $19 by Stifel on China concerns
Stifel has lowered its price target for STAAR Surgical (NASDAQ:STAA) to $19 from $28, while maintaining a Hold rating due to ongoing uncertainty in the Chinese refractive market. The firm noted that despite STAAR's Implantable Collamer Lens gaining market share in China, procedure volumes remain soft. Stifel awaits signs of improvement in the Chinese market and management stability before adopting a more positive outlook.
Leadership watch: Staar Surgical names co-CEOs, ACET adds to Board
STAAR Surgical has appointed Deborah Andrews and Warren Foust as interim co-CEOs following the departure of Stephen C. Farrell, who stepped down as part of a cooperation agreement with Broadwood Partners. Concurrently, the American College of Eye Technicians (ACET) has added Hayley G. Boling, CEO of Boling Vision Center, to its volunteer advisory board to further its mission of expanding the eyecare workforce. A global search is underway for STAAR Surgical's permanent leader.
STAAR Surgical stock price target lowered to $19 by Stifel on China concerns
Stifel has lowered its price target for STAAR Surgical (NASDAQ:STAA) to $19 from $28, maintaining a Hold rating, due to concerns over the soft procedure volume trends in China's refractive market. The stock has underperformed since August, and Stifel awaits improved market conditions in China and management stability with a new CEO before becoming more optimistic. Other analysts like Morgan Stanley and Canaccord Genuity have also adjusted their ratings and price targets for STAAR Surgical.
Staar Surgical Announces Chief Legal Officer Transition Plan
Staar Surgical (STAA) has announced the termination of employment for its Chief Legal Officer, Nathaniel Sisitsky, effective February 4, 2026, categorized as a termination without cause. Sisitsky will provide transition-related legal consulting services until March 13, 2026, and will receive a severance package including 12 months of base salary, benefits, his 2025 annual bonus, and a $75,000 cash recognition award. Restricted stock units set to vest in March 2026 were accelerated, while other unvested equity was forfeited, indicating a managed leadership transition.
STAAR Surgical Company (STAA): A Bull Case Theory
This article summarizes a bullish thesis on STAAR Surgical Company (STAA), highlighting a unique special-situations setup stemming from its attempted acquisition by Alcon. Shareholder resistance, led by Broadwood, argues that the $28 per share offer undervalues STAA following a temporary dip in China sales, despite Alcon previously offering $58. This situation creates a rich catalyst stack involving merger arbitrage, activism, and a potential bidding war, suggesting significant upside if the deal is rejected and fundamentals improve.
STAAR Surgical (NASDAQ:STAA) Now Covered by Wedbush
Wedbush initiated coverage on STAAR Surgical (NASDAQ:STAA) with a "neutral" rating and a $26.00 price target. This implies a 44.1% upside, though overall analyst sentiment is mixed-to-negative with a "Reduce" consensus rating and a $21.36 price target. The article notes significant insider and institutional activity, with major shareholder Broadwood Partners and other insiders purchasing shares, while institutional ownership stands at 96.7%.
STAAR Surgical Names Warren Foust and Deborah Andrews Interim Co-CEOs
STAAR Surgical Company has appointed Warren Foust and Deborah Andrews as interim co-chief executive officers, effective February 1, 2026. The board of directors has initiated a global search for a new CEO, considering both internal and external candidates. This change follows recent board appointments and the termination of a merger agreement with Alcon, as reported earlier by VM.
Staar Surgical (STAA) to Report Q4 Results: Wall Street Expects Earnings Growth
Staar Surgical (STAA) is anticipated to report an increase in Q4 earnings and revenues year-over-year. Despite this outlook, the consensus EPS estimate has been revised significantly lower by 500% over the past 30 days. The company's Earnings ESP and Zacks Rank #4 suggest it's difficult to predict an earnings beat, though Staar Surgical has exceeded consensus EPS estimates in three of the last four quarters.
Why STAAR Surgical (STAA) Stock Is Trading Lower Today
Shares of STAAR Surgical (STAA) fell 3.5% after the company announced a leadership transition, appointing interim co-CEOs following the resignation of its chief executive. This change introduces uncertainty, especially given investors had recently rejected a takeover deal. The company's board has initiated a global search for a permanent CEO to guide its future direction.
STAAR Surgical Names Warren Foust and Deborah Andrews Interim Co-CEOs
STAAR Surgical Company has appointed Warren Foust and Deborah Andrews as interim co-chief executive officers, effective February 1, 2026. Foust, president and chief operating officer, and Andrews, chief financial officer, will lead the company while the board conducts a global search for a new CEO. This leadership change follows recent shifts on the board of directors and the termination of a merger agreement with Alcon.
Two top finance and ops leaders step in as STAAR Surgical hunts new CEO
STAAR Surgical has appointed Warren Foust, President and COO, and Deborah Andrews, CFO, as interim co-Chief Executive Officers, effective February 1, 2026, while the company searches for a permanent CEO. A global search committee has been formed, engaging executive search firms to evaluate both internal and external candidates. Foust will oversee global sales, marketing, manufacturing, and operations, and Andrews will manage finance, accounting, IT, and investor relations.
Why STAAR Surgical (STAA) Stock Is Trading Lower Today
STAAR Surgical (STAA) shares fell 3.5% after the company announced a leadership transition, appointing interim co-CEOs following the resignation of its chief executive. This transition comes after investors rejected a takeover deal, adding uncertainty to the company's future. The board has initiated a global search for a permanent CEO.
STAAR Surgical Appoints Warren Foust and Deborah Andrews Interim Co-CEOs
STAAR Surgical Company has appointed Warren Foust and Deborah Andrews as interim co-Chief Executive Officers, effective February 1, 2026. Mr. Foust, President and COO, and Ms. Andrews, CFO, will lead the company during the transition while a global search is conducted for a new CEO. The Board's Search Committee, comprising several directors, is actively engaging with executive search firms and evaluating both internal and external candidates for the position.
Staar Surgical names interim co-CEOs in leadership shift following failed Alcon deal
Staar Surgical has appointed Warren Foust and Deborah Andrews as interim co-CEOs following the departure of former CEO Stephen Farrell and Chair Elizabeth Yeu. This leadership change comes after a $1.5 billion merger deal with Alcon fell through last month. Foust and Andrews, who hold existing leadership roles, will manage day-to-day operations while the company searches for a permanent CEO.
STAAR Surgical Appoints Warren Foust and Deborah Andrews Interim Co-CEOs
STAAR Surgical has appointed Warren Foust and Deborah Andrews as interim co-Chief Executive Officers, effective February 1, 2026. This decision follows the establishment of a Search Committee by the Board of Directors, which has already initiated a global search for a new CEO. Foust previously served as President and Chief Operating Officer, while Andrews was the Chief Financial Officer; both bring extensive experience within STAAR Surgical and the medical device industry to their new roles during this transitional period.
A month after Alcon deal fell through, Staar Surgical searches for next CEO and names interim leaders
Staar Surgical is searching for a new CEO after a turbulent start to the New Year, which included the failed Alcon takeover bid and the departure of its previous CEO. Warren Foust and Deborah Andrews have been appointed as interim co-CEOs while a global search for a permanent leader is underway. The company's main products are implantable collamer lenses, and it has faced challenges including declining demand in China and significant organizational changes.
STAAR Surgical Company Announces Interim Co-CEO Appointments, Effective February 1, 2026
STAAR Surgical Company's Board of Directors has appointed Warren Foust and Deborah Andrews as interim co-Chief Executive Officers, effective February 1, 2026. This decision comes as the Board's Search Committee, aided by executive search firms, conducts a global search for a new CEO, considering both internal and external candidates. Foust, previously President and COO, and Andrews, the CFO, will jointly manage the company's daily operations with Board support.
Staar Surgical (STAA) Appoints Interim Co-CEOs as CEO Search Beginners
Staar Surgical (STAA) has appointed Warren Foust (President and COO) and Deborah Andrews (CFO) as interim co-CEOs, effective February 1, while the company searches for a permanent CEO. The company, which specializes in implantable lenses, faces challenges with profitability and operational efficiency despite strong liquidity and gross margins. Valuation metrics suggest a speculative growth status, and analysts recommend a "hold" position.
Staar Surgical Names Interim Co-CEOs Amid Leadership Transition
Staar Surgical has named Warren Foust and Deborah Andrews as interim co-CEOs following the resignation of CEO Stephen C. Farrell. The company's board has initiated a global search for a permanent CEO and has provided retention-focused equity and protections for the interim leaders, particularly Foust. Spark, TipRanks’ AI Analyst, views STAA as Neutral due to poor financial performance, bearish technicals, and mixed corporate events.
Why STAAR Surgical (STAA) Shares Are Down Today
STAAR Surgical (NASDAQ:STAA) shares dropped 3.5% after the announcement of a leadership change, with interim co-CEOs appointed following the former CEO's resignation. This leadership shift introduces uncertainty, especially given the recent rejection of an acquisition proposal by shareholders. The stock is known for volatility, and despite a past surge due to an acquisition offer, it has fallen significantly since the start of the year and from its 52-week high.
Jefferies Lowers Staar Surgical (STAA) Price Target to $21.50 | STAA Stock News
Jefferies has lowered its price target for Staar Surgical (STAA) to $21.50 from $28.00, while maintaining a "Buy" rating. This adjustment reflects current market conditions and analyst assessments, with other firms also showing varied price target changes. Staar Surgical, a manufacturer of implantable eye lenses, has an average analyst target price of $22.25 and a GuruFocus estimated fair value of $36.70.
Jefferies Lowers Staar Surgical (STAA) Price Target to $21.50
Jefferies has lowered its price target for Staar Surgical (STAA) to $21.50 from $28.00 while maintaining a "Buy" rating. This adjustment follows other recent analyst updates, including both increases and decreases in price targets from firms like Canaccord Genuity and Wells Fargo. Despite the revised price target, the average analyst forecast still implies an upside of 15.70% from the current price, with GuruFocus estimating a significantly higher fair value of $36.70.
Jefferies Financial Group Lowers STAAR Surgical (NASDAQ:STAA) Price Target to $21.50
Jefferies Financial Group has lowered its price target for STAAR Surgical (NASDAQ:STAA) from $28.00 to $21.50, but maintained a "buy" rating, implying a 12.4% upside. Other analysts have varying ratings, including "hold" and "sell," with a consensus "Reduce" rating and an average price target of $20.78. Notable insider activity includes Broadwood Partners acquiring shares and institutional investors holding a significant portion of the stock.
The Truth About STAAR Surgical Co: The Tiny Eye Stock Chasing a Massive Glow-Up
STAAR Surgical Co (STAA) is gaining attention for its implantable Collamer lenses (ICL) which offer permanent vision correction as an alternative to LASIK. The company's technology is becoming popular on social media through before-and-after transformations, positioning it as a premium, elective body upgrade. Investors should consider STAA a high-risk, story-driven stock dependent on increased adoption and awareness, rather than a stable investment.
The Truth About STAAR Surgical Co: Is This Eye Tech Stock About To Blow Up Or Black Out?
The article discusses STAAR Surgical Co (STAA), a medical-device company specializing in implantable lenses for vision correction. It explores whether the stock is a promising investment due to its niche product and potential for global growth, or if its past volatility and market competition make it a risky play. The author advises potential investors to conduct thorough research and consider their risk tolerance before investing.
Analysts Question STAAR Surgical Company (STAA)'s Post-Merger Standalone Valuation
Analysts are questioning the standalone valuation of STAAR Surgical Company (STAA) following the termination of its merger agreement with Alcon. Morgan Stanley resumed coverage with an Underweight rating and a $13 price target, citing the niche nature of STAAR's EVO ICL technology and challenges for expansion, noting the stock is surprisingly trading above pre-merger levels. Canaccord Genuity also lowered its price target to $22 and maintained a Hold rating, shifting its valuation back to STAAR's fundamental performance.
Analysts Question STAAR Surgical Company (STAA)’s Post-Merger Standalone Valuation
Analysts are questioning STAAR Surgical Company's (STAA) valuation after the termination of its merger agreement with Alcon. Morgan Stanley initiated coverage with an Underweight rating and a $13 price target, citing the niche nature of STAAR's EVO ICL technology and challenging expansion. Concurrently, Canaccord Genuity lowered its price target to $22, shifting its valuation framework back to STAAR's standalone fundamentals.
Is STAAR Surgical (STAA) Attractively Priced After Prolonged Share Price Weakness?
STAAR Surgical (STAA) has experienced prolonged share price weakness, with significant declines over the past five years. While a Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 50.2%, its Price to Sales (P/S) ratio of 4.13x is above the industry average and its proprietary "Fair Ratio," indicating it might be overvalued by this metric. The article encourages investors to use "Narratives" on Simply Wall St to align their personal views and financial forecasts for a more complete valuation assessment.
STAAR Surgical Board Overhaul And CEO Search Set Valuation Test
STAAR Surgical (NasdaqGM:STAA) has undergone a significant board overhaul, appointing a new independent Board Chair and three new directors, while also forming a Search Committee to find a successor for the current CEO who is expected to step down by January 2026. This leadership transition comes as the company's stock has seen substantial declines over the past 30 days, year, and long-term, making the governance changes crucial for investors. The article highlights that the stock is currently trading below analyst targets and is considered undervalued by Simply Wall St, but new leadership will need to address margin issues and net income losses.
STAAR Surgical announces board changes as CEO prepares to step down
STAAR Surgical Company (NASDAQ: STAA) has announced significant changes to its board of directors, including the appointment of Neal Bradsher, Richard LeBuhn, and Christopher Wang, as CEO Stephen Farrell prepares to step down by January 31, 2026. These changes are part of a cooperation agreement with Broadwood Partners, a major shareholder. Despite recent revenue declines, the company maintains a strong gross profit margin and a solid cash position, providing financial flexibility for its new leadership.
STAAR Surgical and Broadwood Partners Announce Changes to Leadership, Board of Directors
STAAR Surgical and Broadwood Partners have announced significant changes to STAAR's leadership and board of directors, including the immediate addition of three new board members: Neal C. Bradsher, Richard T. LeBuhn, and Christopher Wang. Concurrently, STAAR chair Elizabeth Yeu and CEO Stephen Farrell have stepped down from the board, with Farrell remaining CEO until January 31, 2026. These changes follow the termination of STAAR's merger agreement with Alcon due to insufficient stockholder votes.
STAAR Surgical (NASDAQ: STAA) CEO exits as Broadwood adds directors
STAAR Surgical has entered a cooperation agreement with its major stockholder, Broadwood Partners, leading to significant changes in its board and leadership. CEO Stephen C. Farrell will step down by January 31, 2026, and three new directors have been appointed, increasing the board size to seven. The company is also temporarily non-compliant with NASDAQ's audit committee requirements due to a director's resignation but plans to regain compliance during the cure period.
STAAR Surgical (STAA) Is Down 6.8% After Governance Shake-Up Post Rejected Alcon Merger - Has The Bull Case Changed?
STAAR Surgical's board recently underwent a significant reshuffle, prompted by shareholders rejecting a merger with Alcon. This change provides major shareholder Broadwood Partners and its allies greater influence, potentially altering the company's governance and capital allocation strategies. The company's investment narrative will now heavily depend on how the new board addresses challenges like China concentration and softness in refractive procedures.
STAAR Surgical Company (NASDAQ:STAA) Given Average Rating of "Reduce" by Brokerages
STAAR Surgical Company (NASDAQ:STAA) has received an average rating of "Reduce" from eleven brokerages, with a mean one-year price target of $21.96. Insider buying has been significant, with major shareholder Broadwood Partners acquiring 27,485 shares, and insiders collectively purchasing nearly 2 million shares in the last 90 days. The stock opened at $20.97, trading below its 50- and 200-day moving averages, and institutional investors own about 96.7% of the company.
STAAR Surgical and Broadwood Partners Announce Changes to Leadership, Board of Directors
STAAR Surgical Company and Broadwood Partners announced significant leadership and board changes. Neal C. Bradsher, Richard T. LeBuhn of Broadwood, and Christopher Wang of Yunqi Capital have joined STAAR's board, while chair Elizabeth Yeu and CEO Stephen Farrell have stepped down from the board. These changes follow STAAR's termination of a proposed merger with Alcon, which had faced considerable opposition from major shareholders like Broadwood.
